Close

Alexion Pharmaceuticals (ALXN) PT Raised to $139 at RBC Capital After Revenue Guidance Increase at Analyst Day Oct 7, 2020 06:08AM
Alexion (ALXN) to Acquire Portola (PTLA) for $18 Per Share May 5, 2020 07:02AM
Alexion to Acquire Portola May 5, 2020 07:00AM
RBC Capital Reinstates Alexion Pharmaceuticals (ALXn) at Outperform Jan 31, 2020 07:21AM
RBC Capital Reinstates Alexion Pharmaceuticals (ALXN) at Outperform Jan 31, 2020 06:26AM


Sep 18, 2019 08:27AM Alexion Pharmaceuticals (ALXN) CFO Successor Is A Strong Replacement - RBC
May 13, 2019 04:30PM Alexion to Present at the RBC Capital Markets Annual Healthcare Conference
Mar 27, 2019 06:30AM Alexion Pharmaceuticals (ALXN) PT Raised to 'Street High' $186 at RBC Capital
Feb 5, 2019 06:42AM Alexion Pharmaceuticals (ALXN) PT Lowered to $165 at RBC Capital
Jan 22, 2019 09:53AM Alexion Pharma (ALXN): Patent Ruling an Incremental Negative, But Competition Years Away - RBC
Dec 10, 2018 01:46PM Alexion Pharma (ALXN) Could Consider Buying Ra Pharmaceuticals (RARX) Outright - RBC
Nov 16, 2018 12:57PM Alexion (ALXN): '1210 Patent Challenge Looks Like a Troll - RBC
Sep 25, 2018 07:26AM Alexion Pharmaceuticals (ALXN) PT Raised to $170 at RBC Capital
May 15, 2018 07:56AM Vertex Pharma (VRTX), Alexion Pharma (ALXN) Least Impacted from Trump Drug Policies - RBC
May 8, 2018 01:47PM Alexion Pharmaceuticals (ALXN) Defended at RBC
Mar 15, 2018 09:41AM RBC Sees 10-15% Move in Alexion Pharma (ALXN) Following ALXN-1210 Results
Oct 24, 2017 06:54AM Alexion Pharmaceuticals (ALXN) PT Raised to $166 at RBC Capital
Sep 14, 2017 04:25PM RBC Capital Starts Alexion Pharmaceuticals (ALXN) at Outperform
Mar 27, 2017 04:13PM RBC Capital Reiterates Outperform Rating and $177 PT on Alexion Pharma (ALXN) Following New CEO Announcement
Feb 17, 2017 08:57AM Alexion Pharmaceuticals (ALXN) PT Lowered to $177 at RBC Capital Following PNH Update
Jan 6, 2017 06:52AM Alexion Pharma (ALXN): Worst Case Scenario Averted - RBC
Dec 22, 2016 08:39AM Alexion Pharma (ALXN): Soliris In DGF Was A Rounding Error - RBC
Dec 13, 2016 07:52AM Alexion (ALXN): Soliris Core Business Alone is Worth $115/Share - RBC
Sep 15, 2016 10:27AM Notable Analyst Rating Changes 9/15: (GPN) (AKRX) (EXTR) Upgraded; (VFC) (FGP) (ATRA) Downgraded
Jul 28, 2016 01:53PM U.S. biotech stocks win back investors in big July run
Jul 12, 2016 05:07PM UPDATE: RBC Capital Starts Alexion Pharmaceuticals (ALXN) at Outperform
Jun 27, 2016 10:24AM Notable Analyst Rating Changes 6/27: (GOLD) (GME) (ALXN) Upgraded; (RMD) (PCAR) (LYB) Downgraded
Jun 11, 2015 08:54AM Dyax Corp (DYAX) Gains on Takeover Speculation
Feb 20, 2013 10:43AM Notable Analyst Rating Changes 02/20: (RDN) (AFL) (ALXN) Upgraded; (BCS) (SAI) (WIN) Downgraded
Apr 23, 2009 10:07AM David Moenning's Daily State of the Markets: 4/23